ASCO 2020：11项中国研究入选口头简报，17项Poster简报

深受当今世界新冠疫情影响，提前于5翌年29日~6翌年2日在芝加哥举行的美国临床学会（ASCO）高峰会今年将首次以线上形式主办，这是目前最大规模的线上盛事。现今，全会的简介选择题确认，共计103个sessions，中会国共计有11项学术研究入选口头报告，17项入选Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

巯基替尼或拉帕替尼加卡培他鹿岛可用HER2+心肌梗死乳腺肿瘤（PHOEBE）：一项III期随机试验车。

艺术节：心肌梗死乳腺肿瘤

写作者：中会国医学科学院养老院徐兵河讲师、马飞讲师，复旦大学原为养老院胡夕春讲师等

简介号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可手术三阴开放性乳腺肿瘤标准病人后卡培他鹿岛持续节拍低剂量的III期试验车（SYSUCC-001）。

艺术节：乳腺肿瘤—均匀分布/区域/常规病人

写作者：中会山大学环境保护其中会心王树森讲师等

简介号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

运用心肌梗死脑的表型特征来预报脑脊液中会循环DNA检验的概率: 新工具抗衡老对手

艺术节：新工具解决原因老原因

写作者：刘美芹 刘科克等

简介号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

多纳非尼对马利拉非尼作为末期肝蛋白肿瘤的一线病人：一项新开关键字、随机、多其中会心II/III期试验车。

艺术节：肺肠道肿瘤—肺腹腔、胰腺和水火

写作者：四川大学华西养老院毕锋讲师、中会国国民解放军南开养老院秦叔逵讲师等

简介号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

中会国末期肝肿瘤病人阿帕替尼主干线病人：一项随机、抗抑郁药印证、临床III期学术研究

艺术节：肺肠道肿瘤—肺腹腔、胰腺和水火

写作者：中会国国民解放军南开养老院秦叔逵讲师、四川大学华西养老院刘秋讲师等

简介号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

末期罹患开放性卵巢肿瘤二次蛋白减灭术的一项随机III期试验车：SOC1 / SGOG-OV2。

研讨：外科肿瘤症

写作者：复旦大学原为中会山养老院臧荣余讲师等

简介：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈肿瘤根治开放性胎盘输精管后常规病人中会的序贯放低剂量对比单独前列腺癌或同步放低剂量（STARS学术研究）：一项随机、印证、新开关键字的III期试验车。

全会：外科肿瘤症

写作者：中会山大学环境保护其中会心黄鹤讲师、刘继红讲师等

简介号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：常规吉非替尼对比低剂量可用可切除的EGFR开放性状的N1-N2期NSCLC-随机III期临床试验车的再次上都求生存深入研究。

研讨：肺肿瘤—非小蛋白均匀分布-区域/小蛋白/其他颈部

写作者：江门市国民养老院吴一龙讲师等

简介号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR开放性状少转回非小蛋白肺肿瘤病人一线嘧啶丝氨酸抑制重新组建或不重新组建积极机动部队均匀分布前列腺癌：III期新开关键字临床随机试验车（SINDAS）的中会期结果（NCT02893332）。

研讨：肺肿瘤-非小蛋白转回

写作者：贵州省国民养老院曾铭讲师等

简介：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对程序开放性死亡者-1（PD-1）的人源化IgG4酵母重新组建阿昔替尼可用心肌梗死发炎黑色素疣病人的Ib期学术研究的总求生存期和生物标志物深入研究。

研讨：黑色素疣/皮肤肿瘤

写作者：北京大学养老院郭军、盛锡楠讲师等

简介：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的可靠开放性和结果：通用CAR-T蛋白首次人体内试验车病人罹患/难治开放性T蛋白急开放性白血球白血病（r/r T-ALL）的可靠开放性和。全会：开发中会的病人技术-免疫病人。写作者：王岂料等简介：3013广告：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利单抗在末期腹腔上皮蛋白蛋白肿瘤病人中会的系统设计：一项随机的新开关键字II期试验车（ORIENT-2）。全会：肺肠道肿瘤-肺腹腔肿瘤、胰腺肿瘤和水火道肿瘤写作者：徐建明讲师等简介：4511广告：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D特异开放性CAR-T蛋白对脾脏母蛋白疣的消弭开放性病人全会：中会枢神经系统写作者：代红久、孙斌、杨东、徐晖、朱贝贝、魏佳、杨旭东简介：2522广告。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在末期错配修复原因病人中会的系统设计全会：开发中会的病人学-免疫病人写作者：沈琳讲师等简介：3021广告。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 骨髓CD7-CART病人罹患/难治开放性ACUTE白血球白血病/淋巴疣的首例人体内临床试验车全会: 开发开放性病人学-免疫病人写作者简介：张明志，杨林等简介：3026广告: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 科克替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度胺（T）重新组建系统设计于末期本体疣病人的Ib期学术研究全会：发展开放性病人学--原子靶向药物和生物学写作者：龚继芳，沈琳讲师等简介：3523广告：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin重新组建紫杉醇和nedaplatin病人罹患开放性或心肌梗死腹腔上皮蛋白蛋白肿瘤（ESCC）病人的II期学术研究。全会：肺肠道肿瘤-肺腹腔、胰腺和水火道肿瘤的学术研究写作者：王志极强，刘玉红，王德申，王凤华，任超，谭琼 王志极强、刘玉红、王德深、王凤华、任超、谭琼简介：4522广告：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.全会：肺肠道肿瘤-肺腹腔肿瘤、胰腺肿瘤和水火管肿瘤的主干线病人写作者：宋艳等简介：4524广告：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种血液外体内环RNA数据集可用初始活检时检验高等级肿瘤的血液外体内环RNA数据集：一项多其中会心的回顾开放性学术研究全会：移行移行系统肿瘤症---肿瘤、睾丸肿瘤和肿瘤写作者简介：Liaoyuan Li等简介：5522广告。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 均匀分布末期宫颈肿瘤比方说低剂量后的常规低剂量全会: 外科肿瘤症写作者简介： 刘珉珉等简介：6031广告：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼病人甲状腺脾脏开放性肿瘤的持续开放性：基于ALTER01031试验车的深入研究。会北京话：头颈部写作者：青岛市养老院高明讲师简介：6526广告。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、一般来说和年龄对安洛替尼病人后病人结局的影响: ALTER01031的亚组深入研究全会：头颈部写作者：青岛市养老院高明讲师简介：6527广告。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA深入研究预报I-IIIA期非小蛋白肺肿瘤（NSCLC）病人术后罹患: GASTO1035和GASTO1018的结果全会：肺肿瘤-非小蛋白均匀分布-地方开放性/小蛋白/小蛋白/其他胸科肿瘤症写作者：Si-Yu Wang等简介：9023广告：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小蛋白肺肿瘤（NSCLC）中会EGFR嘧啶丝氨酸抑制的新型耐药选择开放性全会:肺肿瘤-非小蛋白心肌梗死肺肿瘤写作者简介：杨昕，金小妹，满宇，欧秋香，华宝，薛武，杨少，范敏 杨昕、金小妹、满宇、欧秋香、华宝、薛武、杨绍、范敏简介：9528广告：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1试验车中会末期黑色素疣总求生存的替代往南全会：黑色素疣/皮肤肿瘤写作者：聂润聪，袁书极强，刘元芳，陈英波，周志伟 聂润聪、袁书极强、刘元芳、陈英波、周志伟简介：10030广告：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼病人罹患或心肌梗死原发开放性恶开放性肩胛骨病人的II期学术研究全会： 肉疣写作者：唐丽娜，牛晓辉，许世友，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、王琼、蔡启庆、涂崇奇、范正福、杨瑶简介：11525广告。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 初步高度评价安罗替尼在末期肉疣病人多线病人中会的可靠开放性和。全会：肉疣写作者：姚伟涛，王侯极强，王永，李森，杜新辉，田志浩，牛晓颖 姚伟涛、王侯极强、王永、王鑫、杜鑫辉、田志超、牛晓英简介：11526广告：414